The blood-brain barrier should not be underestimated in neuro-oncology;La barrière hémato-encéphalique: Un facteur clé en neuro-oncologie

Revue Neurologique

Volumn 160, Issue 5 I, 2004, Pages 523-532

  Fortin, D ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Blood brain barrier; Blood brain barrier disruption; Brain tumors; Gliomas; Intra arterial chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; HYPERTONIC SOLUTION; METHOTREXATE; MONOCLONAL ANTIBODY;

BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN LYMPHOMA; BRAIN METASTASIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL PROTOCOL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG SAFETY; GENE THERAPY; GLIOBLASTOMA; HUMAN; INFUSION; NEUROLOGY; NEUROONCOLOGY; OSMOLALITY; OSMOTIC PERMEABILIZATION; REVIEW; SURGICAL ANATOMY; SURVIVAL RATE; TIGHT JUNCTION; TUMOR CELL; VASCULAR ENDOTHELIUM; WATER PERMEABILITY;

EID: 2942746578     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(04)70981-9     Document Type: Review

References (42)

1. ABREY LE, DEANGELIS LM, YAHALOM J. (1998). Long term survival in primary CNS lymphoma. J Clin Oncol, 16: 859-863.
2. ANTONADOU D, PARASKEVAIDIS M, SARRIS G, COLIARAKIS N, ECONOMOU I, KARAGEORGIS P, THROUVALAS N. (2002). Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol, 17: 3644-3650.
3. APUZZO MLJ. (1997). Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas (comment). Neurosurgery, 41: 1038.
4. BHATTACHARJEE AK, NAGASHIMA T, KONDOH T, TAMAKI N. (2001). Quantification of early blood-brain barrier disruption by in situ brain perfusion technique. Brain Res Prot, 8: 126-131.
5. BRIGHTMAN MW, HORI M, RAPOPORT SI, REESE TS, WESTERGAARD E. (1973). Osmotic opening of tight junctions in cerebral endothelium. J Comp Neurol, 152: 317-325.
6. CAIRNCROSS JG, MACDONALD DR. (1988). Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol, 23: 460-464.
7. CLOUGHESY TF, GOBIN YP, BLACK KL et al. (1997). Intraarterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neuro Oncol, 35: 121-131.
8. CROSSEN JR, GARWOOD D, GALSTEIN E, NEUWELT EA. (1994). Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol, 12: 627-642.
9. DOOLITTLE ND, MINER ME, HALL WA et al. (2000). Safety and Efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer, 88: 637-647.
10. DOROVINI-ZIS K, BOWMAN PB, BETZ AL, GOLDSTEIN GW. (1984). Hyperosmotic arabinose solutions open tight junctions between brain capillary endothelial cells in tissue culture. Brain Res, 302: 383-386.
11. TH, KELLY PJ, SCHEITHAUER BW et al. (1988). Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology, 166: 823-827.
12. EHRLICH P. (1906). Uber die Beziehungen von chemische Constituion, Vertheilung, und Pharmakologischer Wirkung: Collected Studies In Immunity. John Wiley. New York: pp. 567-595.
13. FORTIN D, ADAMS R, GALLEZ A. (2004). A blood-brain barrier disruption model eliminating the hemodynamic effect of ketamine. Can J Nerol Sci, 31: 248-253.
14. FORTIN D, CAIRNCROSS GJ, HAMMOND RR. (1999). Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery, 45: 1279-1291.
15. FORTIN D, MCCORMICK CI, REMSEN LG, NIXON R, NEUWELT EA. (2000). Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. Neurosurgery, 47: 199-207.
16. FORTIN D, NEUWELT EA. (2002). Therapeutic manipulation of the blood-brain barrier. Neurobase-neurosurgery. First edition. Medlink CD-ROM.
17. FORTIN D, OSZTIE E, NEUWELT EA. (2000). latrogenic arterial spasm releived by intraarterial mannitol infusion. Am J Neuroradiol, 21: 968-970.
18. Go RS, ADJEI AA. (1999). Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol, 17: 409-422.
19. GUMMERLOCK MK, NEUWELT EA. (1990). The effects of anesthesia on osmotic blood-brain barrier disruption. Neurosurgery, 26: 268-277.
20. HOLSI P, SAPPINO AP, DE TRIBOLET N, DIETRICH PY. (1998). Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol, 6: 589-600.
21. HUNCHAREK M, MUSCAT J. (1998). Treatment of recurrent high grade astrocytoma; results of a systematic review of 1415 patients. Anticancer Res, 18: 1303-1312.
22. KRAEMER DF, FORTIN D, DOOLITTLE ND, NEUWELT EA. (2001). Association of total dose intensity of chemotherapy in primary central nervous system lymphoma and survival. Neurosurgery, 48: 1033-1041.
23. KRAEMER DF, FORTIN D, NEUWELT EA. (2002). Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and futures directions. Curr Neurol Neurosci Rep, 2: 216-224.
24. KROLL RA, NEUWELT EA. (1998). Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery, 42: 1083-1100.
25. MACDONALD DR, CASCINO TL, SCHOLD SC JR, CAIRNCROSS JG. (1990). Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 7: 1277-1280.
26. MCALLISTER LD, DOOLITTLE ND, GUASTADISEGNI PE, KRAEMER DF, LACY CA, CROSSEN JR, NEUWELT EA. (2000). Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery, 46: 51-61.
27. MORTIMER JE, CROWLEY J, EYRE H, WEIDEN P, ELTRINGHAM J, STUCKEY WJ. (1992). A phase II randomized study comparing sequential and combined intraarterial Cisplatin and radiation therapy in primary brain tumors. Cancer, 69: 1220-1223.
28. MULDOON LL, NILAVER G, KROLL RA et al. (1995). Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol, 147: 1840-1851.
29. NEUWELT EA. (1989). Implications of the Blood-Brain Barrier and Its Manipulation. Vol. 1 and 2. Plenum Press. New York.
30. NEUWELT EA, BARNETT PA, HELLSTRŌM I, HELLSTRŌM KE, BEAUMIER P, MCCORMICK CI, WEIGEL RM. (1988). Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res, 48: 4725-4729.
31. PARDRIDGE WM. (1997). Drug delivery to the brain. J Cereb Blood Flow Metab, 17: 713-731.
32. PARDRIDGE WM. (2002). Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol, 59: 35-40.
33. RAPOPORT SI, HORI M, KLATZO I. (1972). Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol, 223: 323-331.
34. REMSEN LG, PAGEL MA, MCCORMACK CI, FIAMENGO S, SEXTON G, NEUWELT EA. (1999). The influence of anesthetic choice, PaCO2, and other factors on osmotic blood brain barrier disruption in rats with brain tumor xenografts. Anesth Analg, 88: 559-567.
35. ROCK JP. (2000). Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model (comment). Neurosurgery, 47: 207.
36. ROMAN-GOLDSTEIN S, CLUNIE DA, STEVENS J, HOGAN R, MONARD J, RAMSEY F, NEUWELT EA. (1994). Osmotic Blood-Brain Barrier Disruption: CT and Radionuclide Imaging. Am J Neuroradiol, 15: 581-590.
37. SARIS SC, BLASBERG RG, CARSON RE. (1991). Intravascular streaming during carotid infusion: demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg, 74: 763-772.
38. SILBERGELD DL, CHICOINE MR. (1997). Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg, 86: 525-531.
39. SHAPIRO WR, GREEN SB, BURGER PC et al. (1992). A randomized comparison of intra-arterial versus intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg, 76: 772-781.
40. YANG W, BARTH RF, CARPENTER DE, MOESCHBERGER ML, GOODMAN JH. (1996). Enhanced delivery of boronophenylalanine by means of intracarotid injection and blood-brain barrier disruption for neutron capture therapy. Neurosurgery, 38: 985-992.
41. YUNG WKA, MECHITLER L, GLEASON MJ. (1991). Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol, 9: 860-864.
42. ZLOKOVIC BV, APUZZO ML. (1997). Cellular and molecular neurosurgery: pathways from concept to reality-part I: target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery, 40: 789-80.